source
- Federal rule forces PBMs to disclose fees and rebates to employersThe Trump administration finalized a regulation that will require pharmacy benefit managers (PBMs) to reveal the various fees and compensation they receive from drugmakers, consultants and other pa…
- Vertex kidney disease drug faces infection risk scrutiny ahead of FDA decisionVertex's kidney disease therapy is expected to receive FDA approval, with the agency's decision scheduled for Nov 30. A previously undisclosed pause rule has drawn attention, raising concerns abou…